Ask about this productRelated genes to: CYB5D2 Blocking Peptide
- Gene:
- CYB5D2 NIH gene
- Name:
- cytochrome b5 domain containing 2
- Previous symbol:
- -
- Synonyms:
- MGC32124
- Chromosome:
- 17p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 2006-01-12
- Date modifiied:
- 2016-06-10
Related products to: CYB5D2 Blocking Peptide
Related articles to: CYB5D2 Blocking Peptide
- Alopecia Areata (AA) is an inflammatory non-cicatricial alopecia with a high prevalence. Some patients with AA show an inferior response to treatment. To find key proteins in AA, Genome-wide association study data from three cohorts were analyzed using Mendelian randomization (MR) method. - Source: PubMed
Publication date: 2025/05/29
Bi LingboWang JingYang JungangZhuang ZhouChen KejunXu ZiningZuo XianboXu JingkaiSheng YujunCui Yong - CYB5D2 is a novel tumor suppressor gene that exhibits ectopic expression in various tumors. This study explored its significance in cervical cancer screening and prognosis by examining its expression in cervical precancerous lesions and cancer tissues and analyzing follow-up data. CYB5D2 expression was comprehensively assessed in 112 clinical samples, combined with routine cervical cancer screening methods to evaluate its early detection potential. Postoperative survival data from cervical cancer patients were analyzed using Kaplan-Meier curves to examine the association between CYB5D2 protein expression and clinicopathological characteristics, as well as its prognostic implications. Results revealed a progressive downregulation of CYB5D2 expression with advancing cervical lesions. Immunohistochemical detection of CYB5D2 protein outperformed ThinPrep cytology test (TCT), DNA aneuploidy analysis, and HR-HPV E6/E7 mRNA testing (mRNA expression of the E6 and E7 genes in high-risk HPV virus) in diagnosing high-grade squamous intraepithelial lesions (HSIL+) of the cervix. Combined testing of TCT, HR-HPV E6/E7 mRNA, and CYB5D2 achieved 100% sensitivity and negative predictive value for HSIL+. In conclusion, low CYB5D2 expression was identified as an independent risk factor for progression-free survival (PFS) in cervical cancer patients. Incorporating CYB5D2 testing into routine screening protocols for squamous cell lesions, along with TCT and HPV testing, may enhance diagnostic efficiency and provide prognostic value for adverse outcomes. - Source: PubMed
Publication date: 2025/05/13
Liu YananZhao GuoqiangKong YanqingZhou FengyuanZhang TongChen XiaohangHu HaiyanWei Fengxiang - Hepatocellular carcinoma (HCC) is a prevalent liver malignancy. This study examined the roles of transforming growth factor beta () and cytochrome b5 domain containing 2 () in HCC etiology and their prognostic biomarker potential. - Source: PubMed
Publication date: 2025/02/28
Jiang DongQi ZhiXu ZhiyingLi Yiran - Lung cancer is a primary global health concern, responsible for a considerable portion of cancer-related fatalities worldwide. Understanding its molecular complexities is crucial for identifying potential targets for treatment. The goal is to slow disease progression and intervene early to prevent the development of advanced lung cancer cases. Hence, there's an urgent need for new biomarkers that can detect lung cancer in its early stages. - Source: PubMed
Publication date: 2025/02/10
Shah Syed Naseer AhmadParveen Rafat - Hepatocellular Carcinoma (HCC) is a type of liver cancer which is characterized by inflammation-associated tumor. The unique characteristics of tumor immune microenvironment in HCC contribute to hepatocarcinogenesis. It was also clarified that aberrant fatty acid metabolism (FAM) might accelerate tumor growth and metastasis of HCC. In this study, we aimed to identify fatty acid metabolism-related clusters and establish a novel prognostic risk model in HCC. Gene expression and corresponding clinical data were searched from the Cancer Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC) portal. From the TCGA database, by unsupervised clustering method, we determined three FAM clusters and two gene clusters with distinct clinicopathological and immune characteristics. Based on 79 prognostic genes identified from 190 differentially expressed genes (DEGs) among three FAM clusters, five prognostic DEGs (CCDC112, TRNP1, CFL1, CYB5D2, and SLC22A1) were determined to construct risk model by least absolute shrinkage and selection operator (LASSO) and multivariate cox regression analysis. Furthermore, the ICGC dataset was used to validate the model. In conclusion, the prognostic risk model constructed in this study exhibited excellent indicator performance of overall survival, clinical feature, and immune cell infiltration, which has the potential to be an effective biomarker for HCC immunotherapy. - Source: PubMed
Publication date: 2023/03/06
Ren ZhixuanGao DuanLuo YueSong ZhenghuiWu GuojingQi NaLi AiminLiu Xinhui